Financial Snapshot

Revenue
$138.7M
TTM
Gross Margin
88.32%
TTM
Net Earnings
-$195.5M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
245.74%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$156.6M
Q3 2024
Cash
Q3 2024
P/E
-7.548
Nov 29, 2024 EST
Free Cash Flow
-$167.8M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $59.61M $3.686M $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change 1517.09%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $59.61M $3.686M $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue $4.987M $754.0K $0.00
Gross Profit $54.62M $2.932M $0.00
Gross Profit Margin 91.63% 79.54%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $185.1M $122.1M $60.97M $21.34M $6.610M $1.800M $700.0K
YoY Change 51.6% 100.3% 185.71% 222.84% 267.22% 157.14%
% of Gross Profit 338.98% 4165.21%
Research & Development $110.6M $182.4M $145.6M $115.3M $36.52M $17.94M $3.410M
YoY Change -39.39% 25.33% 26.23% 215.72% 103.58% 426.1%
% of Gross Profit 202.45% 6222.2%
Depreciation & Amortization $800.0K $600.0K $454.0K $122.0K $68.00K $0.00
YoY Change 33.33% 32.16% 272.13% 79.41%
% of Gross Profit 1.46% 20.46%
Operating Expenses $295.7M $305.3M $206.5M $136.6M $43.13M $19.74M $4.110M
YoY Change -3.14% 47.83% 51.14% 216.81% 118.56% 380.17%
Operating Profit -$241.1M -$301.6M -$206.5M -$136.6M -$43.13M -$19.74M
YoY Change -20.07% 46.05% 51.14% 216.81% 118.56%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $29.71M $15.65M $0.00 $0.00
YoY Change 89.83%
% of Operating Profit
Other Income/Expense, Net $11.79M -$9.831M $173.0K $967.0K $1.136M $480.0K -$870.0K
YoY Change -219.89% -5782.66% -82.11% -14.88% 136.67% -155.17%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$255.7M -$311.5M -$206.4M -$135.7M -$42.00M -$19.26M -$4.980M
YoY Change -17.92% 50.93% 52.09% 223.05% 118.07% 286.75%
Income Tax $3.113M $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$262.1M -$311.5M -$206.4M -$135.7M -$42.00M -$19.26M -$4.980M
YoY Change -15.83% 50.93% 52.09% 223.07% 118.1% 286.65%
Net Earnings / Revenue -439.79% -8449.76%
Basic Earnings Per Share -$3.78 -$5.66 -$4.18 -$3.80 -$22.78
Diluted Earnings Per Share -$3.78 -$5.66 -$4.18 -$3.80 -$22.78 -$525.8K -$136.0K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $271.9M $409.6M $387.1M $284.4M $101.3M $50.90M $3.400M
YoY Change -33.63% 5.82% 36.1% 180.75% 99.02% 1397.06%
Cash & Equivalents $88.40M $53.64M $96.45M $65.10M $63.30M $39.40M $3.400M
Short-Term Investments $183.5M $355.9M $290.6M $219.4M $37.90M $11.50M $0.00
Other Short-Term Assets $19.63M $11.85M $15.35M $7.800M $5.200M $200.0K $400.0K
YoY Change 65.72% -22.84% 96.82% 50.0% 2500.0% -50.0%
Inventory $13.13M $7.514M
Prepaid Expenses
Receivables $25.81M $8.458M
Other Receivables $0.00 $0.00
Total Short-Term Assets $330.4M $437.4M $402.8M $292.8M $106.5M $51.10M $3.800M
YoY Change -24.46% 8.6% 37.56% 174.93% 108.41% 1244.74%
Property, Plant & Equipment $3.900M $4.602M $5.301M $5.400M $500.0K
YoY Change -15.25% -13.19% -1.83% 980.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $596.0K $78.00K $78.00K $100.0K $0.00
YoY Change 664.1% 0.0% -22.0%
Total Long-Term Assets $10.93M $11.87M $5.379M $5.500M $500.0K $0.00 $0.00
YoY Change -7.87% 120.64% -2.2% 1000.0%
Total Assets $341.4M $449.3M $408.2M $298.3M $107.0M $51.10M $3.800M
YoY Change
Accounts Payable $11.99M $8.827M $7.353M $7.100M $1.400M $1.800M $500.0K
YoY Change 35.86% 20.05% 3.56% 407.14% -22.22% 260.0%
Accrued Expenses $34.68M $28.98M $25.97M $15.30M $3.600M $900.0K $200.0K
YoY Change 19.65% 11.58% 69.76% 325.0% 300.0% 350.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.67M $37.81M $33.33M $22.60M $5.200M $2.700M $700.0K
YoY Change 23.44% 13.45% 47.46% 334.62% 92.59% 285.71%
Long-Term Debt $201.8M $197.8M $72.35M $0.00 $0.00 $0.00 $1.000M
YoY Change 2.04% 173.35% -100.0%
Other Long-Term Liabilities $4.231M $4.117M $4.799M $5.000M $300.0K $200.0K $0.00
YoY Change 2.77% -14.21% -4.02% 1566.67% 50.0%
Total Long-Term Liabilities $206.0M $201.9M $77.15M $5.000M $300.0K $200.0K $1.000M
YoY Change 2.05% 161.68% 1442.98% 1566.67% 50.0% -80.0%
Total Liabilities $252.7M $239.7M $110.5M $27.60M $5.600M $2.800M $1.700M
YoY Change 5.43% 116.97% 300.27% 392.86% 100.0% 64.71%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 69.31M shares 55.03M shares 49.41M shares 35.67M shares 1.843M shares
Diluted Shares Outstanding 69.31M shares 55.03M shares 49.41M shares 35.67M shares 1.843M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.4759 Billion

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 296 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Industry: Pharmaceutical Preparations Peers: Vericel Corp Avid Bioservices, Inc. Emergent BioSolutions Inc. ENANTA PHARMACEUTICALS INC FIBROGEN INC Gossamer Bio, Inc. Kymera Therapeutics, Inc. MADRIGAL PHARMACEUTICALS, INC. Sana Biotechnology, Inc.